ClinicalTrials.gg
TerminatedNCT05625087SAFIR 03Updated Oct 14, 2026

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

A Phase 2 interventional study of Alpelisib and Ribociclib in Breast Cancer Stage IV, sponsored by UNICANCER. Terminated at 44 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by UNICANCER · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
poor accrual
Updated Oct 14, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.

Enrollment
36th of 38
4 · median 44
Started
2023
with 3 others
Phase 2
15 of 38
2 open now
Registered
35th of 38
by date
Lead sponsor
2 of 38
UNICANCER

Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 36th largest by enrollment, is one of 4 that started in 2023, is one of 15 in phase 2, and was the 35th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About alpelisib

Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing alpelisib in Breast Neoplasms, or all of them as a file.
02

Study summary

After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was designed as a randomised, open-label, multicentre, phase II study, for comparison of alpelisib to ribociclib in combination with fulvestrant (as the continuation of the CDK4/6 inhibitor-fulvestrant strategy) in terms of progression-free survival (PFS).

Read the detailed description

INDICATION The population eligible to the screening phase is composed of all women or men with HR+, HER2- metastatic breast cancer who are eligible for first-line treatment with a cyclin-dependent kinases (CDK) 4/6 inhibitor combined with fulvestrant (and a luteinizing hormone realeasing hormone (LH-RH) analogue in men and premenopausal women) in the context of the standard healthcare management. The screening will identify patients with high risk of relapse on any CDK4/6 inhibitor thanks to ctDNA kinetic between baseline and 4 weeks of treatment. The purpose is to early adapt the therapeutic intervention for ctDNA no drop patient to prevent from relapse. This study will propose an intervention for PIK3CA mutated patients with alpelisib vs. ribociclib. Other therapeutic approaches might be proposed to patients with wild type PIK3CA through other protocols.

The randomised study phase will include patients with persistent mutations on exons 4, 9 or 20* of PIK3CA ctDNA after 4 weeks of treatment with any CDK4/6 inhibitor-fulvestrant in first-line setting.

03

Conditions studied

  • Breast Cancer Stage IV

Browse trials for

Keywords

  • metastatic Breast Cancer
  • HER2-
  • RH+
  • PIK3CA mutated
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

SCREENING PHASE (SAFIR 03 - SCREENING)

Inclusion Criteria:

  1. Patient must have signed a written prior to any study-specific screening procedures (the consent form specifically for the screening phase must be signed).
  2. Patient is ≥18 years of age.
  3. Patient has an or cytologically confirmed breast cancer.
  4. Patient has a - breast cancer (without HER2 overexpression according to the ASCO-CAP 2018 guidelines).
  5. Patient has hormone receptor-positive (HR+) breast cancer, defined as having oestrogen receptor (ER) and/or progesterone receptor (PR) expression in ≥10% of tumour cells.
  6. Patient had a metastatic relapse during or within 1 year after termination of the endocrine therapy.
  7. Patient has not yet been treated in the metastatic breast cancer setting.
  8. Patient is eligible for a treatment with a marketed CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) in combination with fulvestrant, according to its marketing authorisation.
  9. (ECOG) performance status is ≤1.
  10. Patient has an adequate bone marrow and organ function.
  11. Measurable or evaluable disease according to version 1.1 (RECIST v1.1).
  12. Patients must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures.
  13. Patient must be affiliated to the national social security (or equivalent).

Exclusion Criteria:

  1. Prior exposure to PIK3CA-AKT or CDK4/6 inhibitors.
  2. Patient that has initiated the CDK4/6 inhibitor treatment.
  3. Patient with spinal cord compression and/or symptomatic or progressive (unless asymptomatic or treated and stable off for ≥30 days before initiating the study treatment).
  4. Participant with an established diagnosis of diabetes mellitus type I or not controlled type II (based on FG and ).
  5. Patient unable to swallow tablets.
  6. Patient with known to any of the study treatment , in particular patients with allergies to soya or peanuts.
  7. Patients with a history of malabsorption syndrome or other condition that may interfere with enteral absorption: including but not limited to active intestine inflammation (e.g., Crohn's disease or ulcerative colitis) requiring therapy.
  8. Patient with any condition/disease for which the investigator considers that participating in the study is inappropriate or that may jeopardize treatment and protocol compliance.
  9. Patient deprived of liberty or under the authority of a tutor.

RANDOMISED PHASE ( SAFIR 03 -ARRIBA)

Inclusion Criteria:

  1. Patient must have signed a written informed consent prior to any procedures for the randomised study phase (the consent form specifically for the randomised study phase must be signed).
  2. Patient has a circulating PIK3CA level of exon 4, 9 or 20 mutant* of PIK3CA ctDNA determined by circulating tumour DNA (ctDNA) assay after 4 weeks of treatment with any CDK4/6 inhibitor combined with fulvestrant.
  3. Patient must have discontinued CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) at least 7 days before randomisation.
  4. ECOG performance status is ≤1.
  5. Patient's is deemed ≥3 months.
  6. Patient has an adequate bone marrow and organ function as defined by the following laboratory values:

    • (ANC) ≥1500/mm³,
    • count ≥100,000/mm³,
    • ≥9.0 g/dL,
    • (INR) ≤1.5 (unless the participant is receiving anticoagulants and the INR is within the therapeutic range of intended use for that anticoagulant within 7 days prior to the first dose of study drug),
    • Serum creatinine ≤1.5 × (ULN) or ≥50 mL/min,
    • Total ≤2× ULN (\<3 ULN with documented Gilbert's disease) or direct bilirubin ≤ 1.5 × ULN,
    • (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN, or \<5.0 x ULN if patient has liver metastasis,
    • Fasting Serum amylase ≤ 2 × ULN,
    • Fasting Serum lipase ≤ ULN,
    • Fasting plasma glucose (FPG) ≤140 mg/dL (or ≤7.7 mmol/L) and glycosylated haemoglobin (HbA1c) ≤6.4%.
  7. Participant must have the following laboratory values within normal limits or corrected to within normal limits with supplements before randomisation

    • Potassium
    • Magnesium
    • Total Calcium (corrected for serum albumin)
  8. Patient with parameters of standard 12-lead (defined as the mean of triplicate ECGs performed) as follows, before randomisation:

    • interval \<450ms (using Fridericia's correction),
    • Resting heart rate between 50-90 bpm.
  9. Women of must have a negative serum pregnancy test result within 14 days of enrolment in the randomised trial phase.
  10. Men or Women of childbearing potential must agree to the use of effective for the study duration and for at least 2 year after the last dose of study treatment for women, and at least 21 days for men.
  11. Patients must be willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Also numbered exon 5, 10 and 21 according to recent classification: Ensembl Transcript ID: ENST00000263967.4, RefSeq: NM_006218.4.

Exclusion Criteria:

  1. Patient is eligible to chemotherapy because of visceral crisis.
  2. Pregnant or lactating women.
  3. Patient has received more than 2 cycles of the ongoing CDK4/6 inhibitor treatment combined with fulvestrant before randomisation.
  4. Patient has interrupted the ongoing CDK4/6 inhibitor treatment for more than 14 days before randomisation.
  5. Patient has evidence of clinical or radiological disease progression before randomisation.
  6. Patient has unresolved adverse events (grade ≥1), except alopecia and grade ≥2 unresolved adverse events related to fulvestrant or the LH-RH analogue which are acceptable to randomisation.
  7. Patient is considered at high medical risk because of severe or uncontrolled systemic disease, including but not limited to diabetes mellitus, pulmonary disease, clinically significant neurological disorder, chronic pancreatitis, chronic active hepatitis, active untreated/uncontrolled fungal, bacterial, or viral infections, as well as known active viral infections with , , or (HIV).
  8. Participant has currently documented pneumonitis/interstitial lung disease (the chest CT scan performed before start of study treatment for the purpose of tumour assessment should be reviewed to confirm that there are no relevant pulmonary complications present).
  9. Participant has a history of severe cutaneous reaction, such as Stevens-Johnson Syndrome (SJS), Erythema Multiforme (EM), Toxic Epidermal Necrolysis (TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
  10. Participant with unresolved osteonecrosis of the jaw.
  11. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities including any of the following:

    • Uncontrolled hypertension,
    • Symptomatic congestive heart failure: (NYHA) class ≥2,
    • Unstable angina pectoris,
    • Stroke or myocardial infarction within the 6 months before randomisation,
    • Serious cardiac arrhythmia requiring treatment, except treated atrial fibrillation and paroxysmal supraventricular tachycardia, or conduction abnormality for which the patient is no longer at risk of serious arrhythmia (e.g., Patient with Wolff-Parkinson-White syndrome treated with surgical ablation),
    • (LVEF) \<50% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) before randomisation.
    • Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following before randomisation:

      • Presence of risk factors for Torsades de Pointe, including uncorrected hypokalaemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia,
      • Concomitant use of medication(s) known to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to initiating the study treatment) or cannot be replaced by a safe alternative,
      • Unable to determine the QTcF (using Fridericia's correction),
    • Systolic blood pressure (SBP) >160 mmHg or \<90 mmHg.
  12. Patient who has received radiotherapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to starting study drug, or who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom ≥ 25% of the bone marrow was irradiated
  13. Patient is currently consuming any of the following foods, supplements, herbal preparations or medications that cannot be discontinued within 7 days of initiating the study treatment:

    • Known strong inducers or inhibitors of /5 (including grapefruits),
    • Medications predominantly metabolised through CYP3A4/5, with a narrow therapeutic window,
  14. Patient has known hypersensitivity to any of the study treatment excipients, in particular patients with allergies to soya or peanuts.
  15. Patient is or plans to participate in another interventional therapeutic clinical trial. Concurrent participation in an observational study is acceptable.
  16. Patient has , other than that under study, except for adequately treated cone-biopsied in situ carcinoma of the cervix and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, with no evidence of relapse/recurrence within ≥5 years, and at negligible risk for recurrence are eligible for the study.
  17. Patient has any condition/disease, for which the investigator considers that participating in the trial is inappropriate or that may jeopardize treatment and protocol compliance.
  18. Patient deprived of liberty or under the authority of a tutor.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    ALPELISIB ARM

    Oral alpelisib (300 mg daily, in 28-day cycle) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice

    Drug: Alpelisib

  • Active comparator
    RIBOCICLIB ARM

    Oral ribociclib (600 mg daily, 3 weeks on, then 1 week off treatment in 28-day cycles) and fulvestrant as per standard practice. Moreover, men and premenopausal women will receive an LH-RH analogue (goserelin, leuprorelin, or triptorelin) every 28 days ±3 days, as per standard practice.

    Drug: Ribociclib

Interventions

  • Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days

    Also known as: Fulvestrant

  • Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days

    Also known as: Fulvestrant

This study also gives FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival in the study groups

    The PFS is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.

    Time frame: From randomization to disease progression or death, up to 5 years

Secondary outcomes

  1. Overall Survival in the study groups

    Overall survival (OS) is the length of time from randomization that patients enrolled in the study are still alive.

    Time frame: From randomization to death, up to 5 years

  2. Objective response Rate (ORR) in the study groups

    Objective response rate (ORR) is the percentage of patients with a best response during treatment being either complete response (CR) or partial response (PR).

    Time frame: 5 years

  3. Duration of response in the study groups

    Duration of response (DoR) is defined as the time interval from the date of first documented CR or PR to the date of first documented disease progression or death, from any cause.

    Time frame: 5 years

  4. Clinical Benefit Rate in the study groups

    Clinical benefit rate (CBR) is defined as the proportion of patients with a best overall response of CR, PR, or stable disease during treatment.

    Time frame: 5 years

  5. Time to Response in the study groups

    Time to response (TTR) is defined, for subjects with an objective response (OR), as the time from randomisation to the first documentation of OR which is subsequently confirmed.

    Time frame: From randomization to death, up to 5 years

  6. To validate that randomised patients with residual PIK3CA on ctDNA present a poor outcome compare to non-randomised patient

    For this outcome, PFS is defined as the time interval between the date of initiation of standard of care to the date of the first documented disease progression or death, whatever the cause.

    Time frame: From the date of initiation of standard of care to death, up to 5 years

  7. Safety in each study groups.

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout study completion, up to 5 years

  8. Overall Survival (OS) in non-randomised patients

    For non-randomised patients, OS is the length of time from the date of initiation of standard of care that patients enrolled in the study are still alive.

    Time frame: From the date of initiation of standard of care to death of any cause, up to 5 years

  9. Progression Free Survival (PFS) in non-randomised patients

    For non-randomised patients, PFS is the length of time during and after the treatment of a disease with the standard of care that a patient lives with the disease but it does not get worse.

    Time frame: From randomization to death, up to 5 years

07

Study locations

44 sites
  • CHU Amiens Picardie
    Amiens, 80054, France
  • Clinique de l'Europe Amiens - CTHE
    Amiens, 80090, France
  • Centre Hospitalier d'Auxerre
    Auxerre, 89000, France
  • Sainte Catherine Institut du Cancer Avignon Provence
    Avignon, 84918, France
  • Centre Hospitalier de la Côte Basque
    Bayonne, 64100, France
  • Centre Hospitalier de Beauvais
    Beauvais, 60021, France
  • Hôpital Simone Veil de Blois
    Blois, 41000, France
  • Institut Bergonié
    Bordeaux, 33000, France
  • Centre Hospitalier de Boulogne-sur-Mer
    Boulogne-sur-Mer, 62321, France
  • CHRU Morvan
    Brest, 29200, France
  • Clinique Pasteur Lanroze - CFRO - Groupe Vivalto Santé
    Brest, 29200, France
  • Centre François Baclesse
    Caen, 14000, France
  • Hôpital NOVO
    Cergy-Pontoise, 95303, France
  • Centre Hospitalier William Morey
    Chalon-sur-Saône, 71100, France
  • Centre Hospitalier de Cholet
    Cholet, 49300, France
  • Pôle Santé République (ELSAN)
    Clermont-Ferrand, 63000, France
  • Centre Jean Perrin
    Clermont-Ferrand, 63011, France
  • Centre Hospitalier Alpes Léman
    Contamine-sur-Arve, 74130, France
  • Clinique de Flandre
    Coudekerque-Branche, 59210, France
  • CHI Fréjus-Saint-Raphaël
    Fréjus, 83608, France
  • Groupe Hospitalier Mutualiste de Grenoble (GHMG)
    Grenoble, 38028, France
  • CHD Vendée
    La Roche-sur-Yon, 85925, France
  • Centre Hospitalier de Versailles - Hôpital André Mignot
    Le Chesnay, 78150, France
  • Polyclinique de Limoges - Site François Chénieux
    Limoges, 87000, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Hôpital privé Jean Mermoz
    Lyon, 69008, France
  • Clinique de la Sauvegarde
    Lyon, 69009, France
  • Institut Paoli Calmettes
    Marseille, 13009, France
  • ICM Val d'Aurelle
    Montpellier, 34298, France
  • Medipôle de Nancy - COG-ILC (Polyclinique de Gentilly)
    Nancy, 54100, France
  • Clinique Hartmann
    Neuilly-sur-Seine, 92200, France
  • Centre Antoine Lacassagne
    Nice, 06189, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Groupe Hospitalier Diaconesses Croix Saint-Simon
    Paris, 75020, France
  • Centre Hospitalier de Pau
    Pau, 64046, France
  • Hôpital Privé des Côtes-d'Armor (HPCA) - Cario
    Plérin, 22190, France
  • Institut Godinot
    Reims, 51100, France
  • Centre Eugène Marquis
    Rennes, 35042, France
  • CHP Saint-Grégoire - Groupe Vivalto Santé
    Saint-Grégoire, 35760, France
  • Clinique Sainte-Anne - GH Saint-Vincent
    Strasbourg, 67000, France
  • Hôpitaux du Léman
    Thonon-les-Bains, 74200, France
  • Institut Claudius Regaud - IUCT-O
    Toulouse, 31059, France
  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, 54519, France
  • Gustave Roussy
    Villejuif, 94805, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2023 to primary completion in Mar 2025, 17 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2028 → Mar 2025 and completion Jun 2030 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 22, 2022
StartActual
Oct 19, 2023
Primary completionActual
Mar 30, 2025was Jul 2028
CompletionActual
Jan 20, 2026was Jun 2030
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated poor accrual
changed Oct 14, 2026
Primary completion
Jul 2028→Mar 30, 2025 (actual)
Oct 14, 2026
Study completion
Jun 2030→Jan 20, 2026 (actual)
Oct 14, 2026
Enrollment
162 (estimated)→4 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Terminated
    Why stopped poor accrual
    Primary completion Jul 2028→Mar 30, 2025 (now actual)
    Study completion Jun 2030→Jan 20, 2026 (now actual)
    Enrollment 162 (estimated)→4 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05625087
Lead sponsor
UNICANCER
Collaborators
Novartis, Breast Cancer Research Foundation
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Oct 19, 2023
Primary completion
Mar 30, 2025
Completion
Jan 20, 2026
Last update
Oct 14, 2026

Study contacts

Fabrice ANDRE
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion